What is Modalis Therapeutics?
Modalis Therapeutics Corporation is a pioneering biotechnology firm dedicated to the development of novel treatments for genetic diseases. Leveraging its proprietary CRISPR-GNDM genome editing platform, the company specializes in epigenome editing technology. This advanced approach allows for the precise control and targeting of specific genes to address the root causes of diseases. By selectively modulating gene expression, Modalis aims to restore the body's natural protein production balance, a critical factor in maintaining health. The company's innovative therapeutic strategies are designed to benefit patients with a range of genetic disorders and are also positioned for potential collaborative development with pharmaceutical partners.
How much funding has Modalis Therapeutics raised?
Modalis Therapeutics has raised a total of $26M across 2 funding rounds:
Series B
$15M
Series A
$11M
Series B (2019): $15M, investors not publicly disclosed
Series A (2019): $11M led by IDG Capital
Key Investors in Modalis Therapeutics
IDG Capital
IDG Capital is a prominent investment firm known for its focus on technology and healthcare sectors, likely providing strategic guidance and capital to support Modalis Therapeutics' growth.
What's next for Modalis Therapeutics?
The recent major strategic investment in Modalis Therapeutics signals a pivotal moment for the company, likely enabling an acceleration of its research and development pipeline. This capital infusion is expected to fuel the advancement of its epigenome editing platform and the progression of its therapeutic candidates through clinical trials. The company's focus on genetic diseases, coupled with its sophisticated gene editing technology, positions it for significant growth and potential market leadership in the precision medicine sector. Future endeavors will likely involve expanding its portfolio of treatments and forging strategic alliances to broaden its reach and impact.
See full Modalis Therapeutics company page
